Xolair (Omalizumab) Therapy Overview
Xolair is a humanized monoclonal antibody that binds to circulating IgE, preventing it from attaching to mast cells and basophils, thereby blocking the allergic cascade. It is administered as a subcutaneous injection and is FDA-approved for multiple indications including moderate-to-severe allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy 1.
Mechanism of Action
Omalizumab selectively binds to free IgE in the blood, preventing IgE from binding to high-affinity receptors (FcεRI) on mast cells, basophils, and dendritic cells. This leads to:
- Down-regulation of FcεRI receptors on these cells
- Reduced release of inflammatory mediators (IL-4, IL-5, IL-13)
- Decreased blood and tissue eosinophils
- Inhibition of IgE-mediated inflammation 1
Approved Indications
Allergic Asthma
- Patients ≥6 years with moderate-to-severe persistent allergic asthma inadequately controlled on inhaled corticosteroids
- Requires positive skin test or in vitro reactivity to perennial aeroallergen
- Significantly reduces exacerbation rates by 26-58% compared to placebo 2
- Improves asthma control, reduces corticosteroid use, and enhances quality of life 3, 4
Chronic Spontaneous Urticaria (CSU)
- Patients ≥12 years who remain symptomatic despite H1-antihistamine treatment
- Response rates: 84% complete, 13% partial in real-world studies 5
- Most complete responders achieve control after 1-2 doses
- Baseline IgE levels do not predict response 5
IgE-Mediated Food Allergy
- Patients ≥1 year for reduction of allergic reactions including anaphylaxis with accidental food exposure
- Significantly increases tolerance to single doses of multiple food allergens 1, 6
Chronic Rhinosinusitis with Nasal Polyps
- Adults ≥18 years as add-on maintenance therapy 1
Administration Protocol
Dosing
- Determined by body weight and baseline serum IgE levels (for asthma)
- Available as 75 mg, 150 mg, or 300 mg prefilled syringes/autoinjectors, or 150 mg vials requiring reconstitution 1
- Administered subcutaneously every 2-4 weeks depending on indication and dose
Critical Safety Monitoring
Before each injection, assess:
- Current health status and recent changes
- Vital signs
- Lung function (peak expiratory flow or FEV1 for asthma patients) 7
Observation periods:
This extended monitoring for initial doses is critical because anaphylaxis can occur at any time, though most reactions (78%) occur within the first 3 doses 7.
Anaphylaxis Risk Management
The risk of anaphylaxis is approximately 0.09-0.2%, but requires specific precautions 7:
Mandatory Pre-Treatment Steps
- Obtain informed consent discussing risks, benefits, and alternatives 7
- Educate patients on signs/symptoms of anaphylaxis 7
- Prescribe epinephrine autoinjector and ensure proper training before starting therapy 7
- Advise patients to carry epinephrine at all times during treatment and for 24 hours after each injection 7
Important Caveats
- Anaphylaxis can occur after the first dose or after many doses (41 total events: 32 within first 3 doses, 9 after 4th or later dose) 7
- Reactions can occur beyond the observation period, including up to 24 hours post-injection 7
- Most reactions occur within 2 hours (28 of 41 events), but delayed reactions beyond 12 hours have been reported 7
Clinical Efficacy
Asthma
- Reduces exacerbations by 26-58% versus placebo 2
- Decreases inhaled corticosteroid requirements
- Improves lung function and quality of life 3, 8
- Optimal duration for evaluating efficacy: 16-32 weeks 3
Chronic Spontaneous Urticaria
- 84% complete response rate in real-world studies 5
- Rapid symptom control, often after 1-2 doses
- Well-tolerated with infrequent, mild adverse events 5
Food Allergy
- Increases threshold for allergic reactions to multiple foods
- Reduces risk of anaphylaxis with accidental exposure 1, 6
Tolerability Profile
Generally well-tolerated with most adverse events mild to moderate 2:
- Most common: Injection-site reactions
- Rare but serious: Anaphylaxis (0.09-0.2%) 7
- No evidence of increased malignancy risk with long-term use 8
- Adverse events occur at similar frequency to placebo in clinical trials 2
Special Considerations
- Latex allergy: The needle cap of 75 mg and 150 mg prefilled syringes contains natural rubber latex derivative; use autoinjector instead 1
- Baseline IgE: Not required for CSU; does not predict response 5
- Vitamin D deficiency and elevated IgE are common comorbidities but do not predict treatment response 5
- Cost: Remains a significant barrier, though biosimilar availability may improve access 9